Patents by Inventor Himanshu M. Kothari
Himanshu M. Kothari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10315993Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.Type: GrantFiled: April 25, 2018Date of Patent: June 11, 2019Assignee: Cadila Healthcare LimitedInventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Publication number: 20180305311Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.Type: ApplicationFiled: April 25, 2018Publication date: October 25, 2018Inventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Patent number: 9957230Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.Type: GrantFiled: May 15, 2017Date of Patent: May 1, 2018Assignee: Cadila Healthcare LimitedInventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Publication number: 20170320823Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.Type: ApplicationFiled: May 15, 2017Publication date: November 9, 2017Inventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Patent number: 9656954Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.Type: GrantFiled: July 4, 2014Date of Patent: May 23, 2017Assignee: Cadila Healthcare LimitedInventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Publication number: 20160068484Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I): processes for the preparation of these novel salts and use thereof.Type: ApplicationFiled: July 4, 2014Publication date: March 10, 2016Applicant: CADILA HEALTHCARE LIMITEDInventors: Mukul R. JAIN, Suresh GIRI, Himanshu M. KOTHARI, Kaushik BANERJEE, Rashmikant KACHHIYA
-
Patent number: 9108972Abstract: The present invention discloses new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine i.e. gentisate, adipate and trifluoro acetic acid salts. The invention also describes the new. crystalline and amorphous forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine gentisate. The present invention also discloses novel crystalline salt form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine hydrochloride and novel crystalline and amorphous salt forms of besylate and process for their preparation and isolation.Type: GrantFiled: March 2, 2012Date of Patent: August 18, 2015Assignee: Cadila Healthcare LimitedInventors: Bipin Pandey, Mayank Ghanshyambhai Dave, Himanshu M. Kothari, Bhavin Shriprasad Shukla
-
Publication number: 20140051856Abstract: The present invention discloses new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine i.e. gentisate, adipate and trifluoro acetic acid salts. The invention also describes the new. crystalline and amorphous forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine gentisate. The present invention also discloses novel crystalline salt form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine hydrochloride and novel crystalline and amorphous salt forms of besylate and process for their preparation and isolation.Type: ApplicationFiled: March 2, 2012Publication date: February 20, 2014Applicant: CADILA HEALTHCARE LIMITEDInventors: Bipin Pandey, Mayank Ghanshyambhai Dave, Himanshu M. Kothari, Bhavin Shriprasad Shukla
-
Publication number: 20130289276Abstract: The invention provides a process for preparing 3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (Formula I), into its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms comprising: a) reacting 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one of formula (III) with a suitable oxidoreductase enzymes or its suitable variants in the presence of suitable conditions and co-factor; and b) isolating 3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one, into its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms.Type: ApplicationFiled: October 10, 2011Publication date: October 31, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sanjeev Kumar Mendirata, Bipin Pandey, Rupal Joshi, Umang Trivedi, Mayank G. Dave, Himanshu M. Kothari, Bhavin Shukla
-
Publication number: 20100298371Abstract: The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98% purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic forms of Solifenacin hydrochloride and Solifenacin oxalate, in pure form.Type: ApplicationFiled: December 2, 2008Publication date: November 25, 2010Inventors: Mayank Ghanshyambhai Dave, Bipin Pandey, Himanshu M. Kothari, Pankaj Ramanbhai Patel